HC Wainwright Issues Negative Estimate for SANA Earnings

Sana Biotechnology, Inc. (NASDAQ:SANA) – Research analysts at HC Wainwright lowered their Q2 2026 EPS estimates for shares of Sana Biotechnology in a report released on Tuesday, May 12th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($0.13) per share for the quarter, down from their previous forecast of ($0.12). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Sana Biotechnology’s current full-year earnings is ($0.59) per share. HC Wainwright also issued estimates for Sana Biotechnology’s FY2026 earnings at ($0.56) EPS.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.01.

Several other brokerages have also recently issued reports on SANA. Rodman & Renshaw began coverage on shares of Sana Biotechnology in a research note on Monday. They issued a “buy” rating and a $16.00 price objective on the stock. Morgan Stanley reaffirmed an “overweight” rating and issued a $12.00 price objective on shares of Sana Biotechnology in a research note on Friday, March 13th. Wedbush raised their target price on shares of Sana Biotechnology from $6.00 to $7.00 and gave the stock an “outperform” rating in a report on Tuesday, April 14th. Zacks Research cut shares of Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 3rd. Finally, Weiss Ratings cut shares of Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 1st. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Sana Biotechnology presently has an average rating of “Moderate Buy” and a consensus price target of $9.50.

Sana Biotechnology Price Performance

Shares of SANA opened at $3.20 on Thursday. The firm’s 50 day moving average is $3.29 and its 200-day moving average is $3.98. The stock has a market capitalization of $890.53 million, a P/E ratio of -3.44 and a beta of 2.17. Sana Biotechnology has a 12-month low of $1.60 and a 12-month high of $6.55.

Institutional Trading of Sana Biotechnology

Institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. lifted its stake in Sana Biotechnology by 180.8% in the third quarter. JPMorgan Chase & Co. now owns 2,135,444 shares of the company’s stock valued at $7,581,000 after acquiring an additional 1,375,029 shares during the last quarter. Baillie Gifford & Co. lifted its stake in Sana Biotechnology by 13.6% in the third quarter. Baillie Gifford & Co. now owns 11,436,503 shares of the company’s stock valued at $40,600,000 after acquiring an additional 1,371,775 shares during the last quarter. Integral Health Asset Management LLC lifted its stake in Sana Biotechnology by 33.3% in the third quarter. Integral Health Asset Management LLC now owns 2,000,000 shares of the company’s stock valued at $7,100,000 after acquiring an additional 500,000 shares during the last quarter. Rafferty Asset Management LLC acquired a new stake in Sana Biotechnology in the third quarter valued at approximately $951,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in Sana Biotechnology in the third quarter valued at approximately $100,000. 88.23% of the stock is currently owned by institutional investors and hedge funds.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.